AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference
AVEO Oncology (Nasdaq: AVEO) announced that CEO Michael Bailey will participate in a panel discussion at the Cantor Fitzgerald Oncology & HemOnc Conference on September 28, 2022, at 10:40 a.m. ET. The panel, titled “Building Combinations: What are the Novel Ideas?”, will focus on innovative strategies in oncology. AVEO is dedicated to improving cancer treatment and currently markets FOTIVDA® (tivozanib) for advanced renal cell carcinoma. The company emphasizes its commitment to diversity and inclusion in its workforce.
- Participation in a prominent oncology conference may enhance AVEO's visibility and networking opportunities.
- Ongoing development of FOTIVDA in immuno-oncology and novel combinations shows a commitment to innovation.
- None.
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that Michael Bailey, president and chief executive officer, will participate in a panel discussion at the Cantor Fitzgerald Oncology & HemOnc Conference. The panel titled “Building Combinations: What are the Novel Ideas?” will be held on Wednesday, September 28th, at 10:40 a.m. eastern time.
If you are interested in arranging a 1x1 meeting at the conference, please contact your Cantor representative. For more details, please see the Calendar of Events section of AVEO Oncology’s corporate website.
About AVEO Pharmaceuticals, Inc.
AVEO is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology and other novel targeted combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the company.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the sections titled “Risk Factor Summary,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” included in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and in other filings that AVEO makes with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.
AVEO Investor Relations Contact:
Hans Vitzthum
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com
(617) 430-7578
Source: AVEO Oncology
FAQ
What is AVEO Oncology's recent conference participation?
When is the Cantor Fitzgerald Oncology & HemOnc Conference?
What product does AVEO Oncology currently market?
